(Q40442306)

20 September 2017

title

Angiotensin II-induced hypertension in mice caused an increase in insulin secretion (English)

1 reference

20 September 2017

Nana Gletsu

1

1 reference

20 September 2017

Thanh N Doan

2

1 reference

20 September 2017

Justin Cole

3

1 reference

20 September 2017

Roy L Sutliff

4

1 reference

20 September 2017

Kenneth E Bernstein

5

1 reference

20 September 2017

publication date

1 February 2005

1 reference

20 September 2017

published in

Vascular Pharmacology

1 reference

20 September 2017

volume

42

1 reference

20 September 2017

issue

3

1 reference

20 September 2017

page(s)

83-92

1 reference

Effect of angiotensin II and bradykinin on insulin-stimulated tyrosine kinase activity of insulin receptor

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Tyrosine kinase activation by the angiotensin II receptor in the absence of calcium signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Replacement of lysine residue 1030 in the putative ATP-binding region of the insulin receptor abolishes insulin- and antibody-stimulated glucose uptake and receptor kinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Insulin resistance in essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Angiotensin II affects basal, pulsatile, and glucose-stimulated insulin secretion in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Crosstalk between insulin and angiotensin II signalling systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Endogenous angiotensin II suppresses insulin signaling in vascular smooth muscle cells from spontaneously hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Suitability of 2-deoxyglucose for in vitro measurement of glucose transport activity in skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Glucose transport and glucose transporters in muscle and their metabolic regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Regulation and expression of a renin-angiotensin system in human pancreas and pancreatic endocrine tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Evidence of abnormalities of insulin metabolism in rats with spontaneous hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Effects of angiotensin II on insulin sensitivity: a placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Dose-response study of the redistribution of intravascular volume by angiotensin II in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Interaction between glucose metabolism and endogenous insulin release in hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Acute effects of blood pressure elevation on insulin clearance in normotensive healthy subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Abnormalities of carbohydrate and lipid metabolism in Dahl rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Smokeless nicotine administration is associated with hypertension but not with a deterioration in glucose tolerance in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

The effects of valsartan on insulin sensitivity in patients with primary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Cross-talk between the insulin and angiotensin signaling systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Low-dose angiotensin II increases glucose disposal rate during euglycemic hyperinsulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

Fiber-type proportions in mammalian soleus muscle during postnatal development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.01.006

10.1016/J.VPH.2005.01.006

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference